Valuation : Nuvectra Corporation

Market Cap 1.7M 1.47M 1.39M 1.26M 2.36M 162M 2.37M 16.47M 6.33M 82.51M 6.38M 6.24M 261M P/E 2017
-1.84x
P/E 2018 -5.02x
Enterprise Value -53.46M -46.11M -43.62M -39.53M -74.13M -5.11B -74.63M -518M -199M -2.6B -201M -196M -8.2B EV / Sales 2017
2.58x
EV / Sales 2018 4.76x
Free-Float
96.76%
Yield 2017 *
-
Yield 2018 -
Manager TitleAgeSince
Chief Executive Officer 78 30/01/2019
Compliance Officer 51 31/12/2014
Director TitleAgeSince
Director/Board Member 67 29/02/2016
Director/Board Member 78 29/02/2016
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+16.67% - - 268K
-1.36%-5.89%-23.76%-0.44% 176B
-0.72%-3.41%-3.26%+12.32% 116B
+0.19%-2.83%+6.30%+80.17% 61.36B
-1.92%-6.01%+7.05%+38.44% 49.42B
+0.81%-3.73%-4.81%-32.56% 48.44B
-1.75%-5.54%+8.93%-20.82% 31.33B
+0.43%-11.10% - - 28.54B
+0.58%+1.84%+36.58%-12.08% 24.37B
+0.49%-7.65%-13.30%+3.79% 21.57B
Average -0.33%-2.90%+1.72%+8.60% 55.78B
Weighted average by Cap. -0.69%-4.90%-6.02%+10.83%

Financials

2017 2018
Net sales 31.84M 27.46M 25.98M 23.54M 44.15M 3.04B 44.44M 309M 119M 1.55B 120M 117M 4.88B 48.83M 42.12M 39.84M 36.1M 67.71M 4.67B 68.17M 473M 182M 2.37B 183M 179M 7.49B
Net income -44.6M -38.47M -36.39M -32.98M -61.85M -4.26B -62.26M -432M -166M -2.17B -167M -164M -6.84B -48.13M -41.52M -39.27M -35.59M -66.74M -4.6B -67.19M -467M -179M -2.34B -181M -177M -7.38B
Net Debt -1.49M -1.29M -1.22M -1.1M -2.07M -142M -2.08M -14.44M -5.55M -72.36M -5.59M -5.47M -229M -55.16M -47.58M -45.01M -40.78M -76.49M -5.27B -77M -535M -205M -2.68B -207M -203M -8.46B
Logo Nuvectra Corporation
Nuvectra Corporation is a neurostimulation company that focuses on helping physicians to improve the lives of people with chronic neurological conditions. The Company's Algovita Spinal Cord Stimulation (SCS) System (Algovita) is the Company's commercial offering and is Conformite Europeene (CE) marked and the United States Food and Drug Administration (FDA) approved for the treatment of chronic pain of the trunk and/or limbs. Its technology platform also has capabilities under development to support other neurological indications, such as sacral nerve stimulation (SNS) and deep brain stimulation (DBS). In addition, its NeuroNexus Technologies, Inc. (NeuroNexus) subsidiary designs, manufactures and markets neural-interface technologies for the neuroscience clinical research market. Its Virtis is an application of the Company's neurostimulation technology platform and its first product for the SNS market. Its subsidiaries include Algostim, LLC (Algostim) and PelviStim LLC (PelviStim).
Employees
-
  1. Stock Market
  2. Stocks
  3. NVTRQ Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!